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The ability to efficiently deliver a drug or gene to a tumor site is dependent on a wide
range of factors including circulation time, interactions with the mononuclear phagocyte
system, extravasation from circulation at the tumor site, targeting strategy, release
from the delivery vehicle, and uptake in cancer cells. Nanotechnology provides the
possibility of creating delivery systems where the design constraints are decoupled,
allowing new approaches for reducing the unwanted side effects of systemic delivery,
increasing tumor accumulation, and improving efficacy. The physico-chemical properties
of nanoparticle-based delivery platforms introduce additional complexity associated
with pharmacokinetics, tumor accumulation, and biodistribution. To assess the impact
of nanoparticle-based delivery systems, we first review the design strategies and
pharmacokinetics of FDA-approved nanomedicines. Next we review nanomedicines under
development, summarizing the range of nanoparticle platforms, strategies for targeting,
and pharmacokinetics. We show how the lack of uniformity in preclinical trials prevents
systematic comparison and hence limits advances in the field.
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INTRODUCTION
Drug therapy often involves the use of small molecules such
as alkylating agents (e.g., busulfan), anti-metabolites (e.g.,
gemcitabine), anti-microtubule agents (e.g., paclitaxel, vin-
cristine), topoisomerase inhibitors (e.g., topotecan), and cyto-
toxic inhibitors (e.g., doxorubicin). These cytotoxic molecules kill
highly proliferative cancer cells, but also other proliferative cells
in bone marrow, the gastrointestinal (GI) tract, and hair follicles,
leading to common side effects such as compromised immune
system, inflammation and ulceration of the GI tract, and hair
loss. Nanotechnology provides the possibility of creating deliv-
ery systems where the design constraints are decoupled, allowing
new approaches for reducing the unwanted side effects of systemic
delivery, increasing tumor accumulation, and improving efficacy.
The development of safe and efficient delivery systems is also
important for advances in human gene therapy (Pack et al., 2005;
Jones et al., 2013). A delivery system must transport a gene with
high efficiency to target cells, with minimal toxicity and immune
response. The main challenges for gene delivery are protecting the
genetic material from degradation in circulation, avoiding degra-
dation by enzymes in endosomes in the target cell, and escaping
from endosomes to reach the nucleus or target compartment
(Mintzer and Simanek, 2009; Zhang et al., 2012).
Key properties for drug and gene delivery systems are biocom-
patibility, stability in circulation, and increasing the fraction of
the dose accumulating in the tumor. Drug toxicity can be reduced
by encapsulating the free drug (e.g., liposomes) or by locally
activating a pro-drug. Stability in circulation can be improved
by developing strategies to minimize protein binding and evade
the immune system. The efficiency of accumulation at a tumor
site can be improved by active targeting of the delivery system
or by increasing extravasation by the enhanced permeation and
retention (EPR) effect.
The FDA-approved nanomedicines in clinical use have
demonstrated the potential for increasing bioavailability, enhanc-
ing drug solubility, active targeting, and high drug loading
(Dawidczyk et al., 2014). However, there remain many chal-
lenges in exploiting advances in nanotechnology and bioengi-
neering to develop systems that will have significant impact
on patient survival rates. The development of delivery systems
remains largely empirical and the lack of standardization of
pre-clinical studies is a barrier to establishing design rules for
nanomedicines. While studies of complex systems with combined
reporting/sensing functions along with drug or gene delivery
may ultimately improve diagnosis and treatment, there are many
fundamental issues that need to be addressed to establish the rela-
tionship between physico-chemical properties, pharmacokinetics,
biodistribution, and survival rates.
Tumor uptake is modulated by the EPR effect (Jain and
Stylianopoulos, 2010; Fang et al., 2011; Torchilin, 2011) and hence
increasing the circulation time generally increases tumor accu-
mulation. A common approach for increasing circulation time
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is to provide a surface coating of polyethylene glycol (PEG).
Whilst PEG coating increases circulation time and hence can
increase tumor accumulation, it also inhibits uptake by tumor
cells (Barenholz, 2012). Furthermore, PEG coating slows but
does not prevent adsorption of opsonins that promote uptake by
macrophages of the liver and spleen. Targeting molecules such
as immunoglobulin-G (IgG) antibodies are opsonins and hence
promote clearance by the mononuclear phagocyte system (MPS)
(Walkey and Chan, 2012). The conjugation of folate to lipo-
somes significantly increases their uptake by tumor-associated
macrophages (Turk et al., 2004).
FDA-APPROVED NANOMEDICINES
There are currently six FDA-approved nanomedicines (Table 1):
brentuximab vedotin and Trastuzumab emtansine, Doxil,
DaunoXome, Marqibo, and Abraxane (Dawidczyk et al.,
2014). Brentuximab vedotin and Trastuzumab emtansine are
antibody-drug conjugates (ADCs), conceptually one of the
simplest nanomedicines with an anticancer drug conjugated to
a targeting molecule. Brentuximab targets the protein CD30,
a glycosylated phosphoprotein expressed by B cells, including
B-cell lymphomas, some leukemias, and melanoma cancer
stem cells (Mullard, 2013; Sassoon and Blanc, 2013; Sievers
and Senter, 2013). Trastuzumab targets the human epidermal
growth factor receptor 2 (HER2) overexpressed in HER2 positive
breast cancer (Lu et al., 2012; Verma et al., 2012). Monomethyl
auristan E (MMAE) (Brentuximab vedotin) and mertansine
(Trastuzumab emtansine) are too toxic to be used alone and
hence coupling to a targeting antibody reduces toxic side effects.
Several drug molecules are conjugated to each antibody via
a valine-citrulline cleavable linker (Brentuximab vedotin) or
covalent linkage (Trastuzumab emtansine) that is enzymatically
degraded in endosomes following uptake. The small number
of FDA-approved ADCs highlights the difficulty in translating
relatively simple nanomedicines to the clinic.
Doxil, DaunoXome, and Marqibo are liposomal
nanomedicines. Doxil is a pegylated liposome about 100 nm in
diameter and encapsulating about 10,000 doxorubicin molecules
(Barenholz, 2012). Encapsulation minimizes side effects, such as
cardiotoxicity, associated with high doses of free doxorubicin.
The concentration of doxorubicin in the liposomes is greater
than the solubility limit and hence most of the drug is in the
solid phase (Barenholz, 2012). The incorporation of cholesterol
increases the bilayer cohesiveness and reduces leakage. These
features minimize osmotic effects and contribute to stability,
with more than 98% of the circulating drug remaining inside
liposomes (Lasic et al., 1992; Gabizon et al., 1994, 2003). The
polyethylene glycol coating is designed to give a long circulation
half time and thereby increase tumor accumulation by the EPR
effect (Immordino et al., 2006; Vllasaliu et al., 2014). While the
Table 1 | Summary of FDA-approved nanomedicines.
Platform Class Drug d (nm) Drug/carrier Key design feature(s) Problem addressed
ratio
Brentuximab vedotin ADC Monomethyl auristan E ∼10 ≤8 Valine-citrulline linker
cleaved by cathepsin in
endosomes
Monomethyl auristan E
(MMAE) is too toxic to be
used alone
Trastuzumab emtansine ADC Mertansine ∼10 ≤8 Non-cleavable linker;
release of drug by
proteolytic degradation of
antibody in endosomes
Mertansine is too toxic to
be used alone
Doxil Liposome Doxorubicin 100 10,000–15,000 Lipid encapsulation for
high drug/carrier ratio,
polyethylene glycol
coating to evade MPS,
crystallization of drug in
liposome minimizes
escape during circulation
Drug toxicity and adverse
cardiac side effects
DaunoXome Liposome Daunorubicin 50 ∼10,000 No polyethylene glycol
coating, targeted by MPS
resulting in slow release
into circulation
Drug toxicity and adverse
cardiac side effects
Marqibo Liposome Vincristine 100 ∼10,000 No polyethylene glycol
coating, targeted by MPS
resulting in slow release
into circulation
Drug toxicity and adverse
side effects
Abraxane Protein carrier Paclitaxel 130 >10,000 Non-specific binding of
paclitaxel to albumin
Overcomes very low
solubility of paclitaxel
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mechanisms of uptake and release are not known, evidence sug-
gests that the liposomes are taken up by endocytosis (Seynhaeve
et al., 2013).
DaunoXome (Gill et al., 1996; Bellott et al., 2001; Lowis
et al., 2006) and Marqibo (Bedikian et al., 2011; Silverman and
Deitcher, 2013) are liposomal formulations of daunorubicin and
vincristine, respectively. In contrast to Doxil, the design strategy
for DaunoXome and Marqibo is to promote uptake by the MPS,
providing a reservoir from which the free drug can enter circula-
tion, similar to a slow infusion. This is achieved by not including
pegylated lipids in the liposomes (Gill et al., 1996; Bellott et al.,
2001; Silverman andDeitcher, 2013). DaunoXome is about 50 nm
in diameter (Gill et al., 1996), and Marqibo is about 100 nm in
diameter (Silverman and Deitcher, 2013).
Abraxane, or nab-paclitaxel (nanoparticle albumin bound),
is lyophilized human serum albumin non-specifically bound
to paclitaxel (Miele et al., 2009). Paclitaxel has very low sol-
ubility and is administered with the toxic non-ionic solvent
Cremophor, which can lead to a wide range of allergic reactions.
On injection, Abraxane particles dissociate into smaller albumin-
paclitaxel complexes or unbound paclitaxel (Yardley, 2013). Since
albumin is abundant in circulation, Abraxane provides a reservoir
of a very low solubility drug in a non-toxic platform. The particles
are about 130 nm in diameter and contain about 10,000 paclitaxel
molecules (Miele et al., 2009).
The pharmacokinetics of these nanomedicines reflects their
design (Table 2). Brentuximab vedotin and Trastuzumab emtan-
sine both have moderate areas under the curve (AUCs), rela-
tively low clearance, and long elimination half-times of 3–4 days
(Younes et al., 2010; Lorusso et al., 2011; Girish et al., 2012;
Lu et al., 2012; Bradley et al., 2013). Doxil has high AUC, low
clearance rate, small distribution volume, and a long elimina-
tion half-time (Barenholz, 2012). These features are largely due
to the polyethylene glycol coating that provides extended evasion
of the MPS and minimizes distribution into peripheral tissues
(Gabizon et al., 1994; Hubert et al., 2000; Lyass et al., 2000;
Hong and Tseng, 2001; Hamilton et al., 2002). DaunoXome
(Gill et al., 1996; Bellott et al., 2001; Lowis et al., 2006) and
Marqibo (Bedikian et al., 2011; Silverman and Deitcher, 2013)
have clearance rates about an order of magnitude larger than
for the ADCs and Doxil, low distribution volumes, and short
elimination half-times on the order of 10 h. The larger AUC
associated with DaunoXome is related to the larger dose range
compared to Marqibo. Abraxane has a fast clearance rate, about
two orders of magnitudes larger than DaunoXome and Marqibo,
large distribution volume, and elimination half-time similar to
DaunoXome and Marqibo (Sparreboom et al., 2005; Ando et al.,
2012). The pharmacokinetics for Abraxane are similar to free
paclitaxel and the other free drugs: low AUC, high clearance rate,
high distribution volume, and short elimination half-time.
Overall it is evident that antibody drug conjugates or lipo-
somes with a pegylated surface have long elimination half-
times, typically of 3–4 days. Increasing elimination half-times
is expected to increase tumor accumulation via the EPR effect.
However, increased tumor accumulation does not necessarily
imply improved efficacy since processes such as transport, uptake,
drug release, and delivery to the appropriate cellular compart-
ment are all downstream of extravasation by the EPR effect.
NANOPARTICLE PLATFORMS, TARGETING MOIETIES
NANOPARTICLE PLATFORMS
The development of a broad range of nanoparticle platforms
with the ability to tune size, composition, and functionality
has provided a significant resource for nanomedicine (Table 3)
(Niemeyer, 2001; Duncan, 2006; Cho et al., 2008; Greco and
Vicent, 2009; Yu et al., 2013). Nanoparticle platforms can be
broadly categorized as organic, inorganic, and hybrid.
Organic nanoparticles have been widely explored for
decades, yielding a large variety of materials, formulations,
imaging modalities, cargo, and targets for cancer therapy.
Table 2 | Summary of pharmacokinetics for FDA-approved nanomedicines and corresponding free drugs from human clinical trials.
Drug Dose mg2/m AUC (mg h/L) CL (L/h) Vd(L) t1/2(h) References
Brentuximab vedotin 90–110 3.2–4.9 0.071–0.075 8.2–10.2 106–144 Younes et al., 2010; Bradley et al., 2013
Trastuzumab emtansine 10–160 0.6–28 0.023–0.070 1.7–3.5 31–98 Lorusso et al., 2011; Girish et al., 2012; Lu
et al., 2012
Doxil 25–80 600–4900 0.023–0.045 2.1–6.4 42–90 Gabizon et al., 1994; Hubert et al., 2000;
Lyass et al., 2000; Hong and Tseng, 2001;
Hamilton et al., 2002
DaunoXome 10–190 17–1700 0.40–0.94 2.9–4.1 2.8–8.3 Gill et al., 1996; Bellott et al., 2001; Lowis
et al., 2006
Marqibo 2.0–2.25 5–15 0.36–0.38 2.6–2.9 9.6–12 Bedikian et al., 2011; Silverman and Deitcher,
2013
Abraxane 150–300 4–10 31–67 900–1700 11–26 Sparreboom et al., 2005; Ando et al., 2012
Doxorubicin 15–72 0.5–3.8 25–72 250–1800 9–29 Erttmann et al., 1988; Jacquet et al., 1990;
Piscitelli et al., 1993; Gabizon et al., 1994
Daunorubicin 40–120 1–19 110–150 200–450 9–24 Bellott et al., 2001; Krogh-Madsen et al., 2012
Paclitaxel 170–330 6–40 15–50 160–530 7.2–7.6 Sparreboom et al., 2005
In most cases, data represent the range of mean or median values for obtained from different doses. For unit conversion we used an average body surface area of
1.7m2, an average body weight of 60 kg, and a blood volume of 5 L.
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Table 3 | Summary of nanoparticle platforms for nanomedicine.
Particle type Composition/Structure Properties Applications
Polymer e.g., PLGA, glycerol, chitosan, DNA;
monomers, copolymers, hydrogels
Some biodegradable Drug delivery; passive release
(diffusion), controlled release
(triggered)
Dendrimer PAMAM, etc. Low polydispersity, cargo,
biocompatible
Drug delivery
Lipid Liposomes, micelles Can carry hydrophobic cargo,
biocompatible, typically 50–500 nm
Drug delivery
Quantum dots CdSe, CulnSe, CdTe, etc. Broad excitation, no photobleaching,
tunable emission, typically 5–100 nm
Optical imaging
Gold Spheres, rods, or shells Biocompatibility, typically 5–100 nm Hyperthermia therapy, drug delivery
Silica Spheres, shells, mesoporous Biocompatibility Contrast agents, drug delivery
(encapsulation)
Magnetic Iron oxide or cobalt-based; spheres,
aggregates in dextran or silica
Superparamagnetic, ferromagnetic
(small remanence to minimize
aggregation), superferromagnetic
(∼10 nm), paramagnetic
Contrast agents (MRI), hyperthermia
therapy
Carbon-based Carbon nanotubes, buckyballs,
graphene
Biocompatible Drug delivery
Organic polymer systems include synthetic polymers [e.g.,
polyethyleneimine (PEI), polyethylene glycol] (Knop et al., 2010;
Nicolas et al., 2013), synthetic hydrogels (e.g., polyacrylamide)
(Ando et al., 2012; Liechty and Peppas, 2012), natural polymers
(e.g., chitosan, hyaluronic acid, alginate, gelatin) (Ando et al.,
2012) and hydrolytically or enzymatically degradable polymers
(e.g., collagen, polylactic acid, polycaprolactone) (Balogh et al.,
2007). Combinations of components and/or monomer units and
incorporation of other building blocks such as DNA contribute
to the flexibility of polymer-based nanoparticle platforms. These
systems can be passively loaded with a cargo, or a cargo can
be incorporated to allow triggered release (Davis et al., 2008).
Particles such as block copolymers, liposomes, and dendrimers
can provide a reservoir for large amounts of cargo. Block copoly-
mers combine the attributes of two or more monomer units
allowing further functionality (Duncan, 2006; Greco and Vicent,
2009). Lipid-based nanoparticles include micelles, liposomes, or
water oil emulsions. Dendrimers are hyperbranched synthetic
polymers for which biodistribution, size, and multifunctionality
can be tuned with a very low degree of polydispersity (Cho et al.,
2008). Proteins (e.g., albumin) (Fuchs and Coester, 2010) and
viruses (Steinmetz, 2010) have also been extensively studied for
drug and gene delivery.
Inorganic nanoparticles provide advantages in function and
properties not possible with organic nanoparticle platforms,
although this is often at the expense of biocompatibility. Examples
of materials include semiconductors (quantum dots) (Gao et al.,
2004; Medintz et al., 2005; Michalet et al., 2005; Park et al., 2011;
Chen et al., 2012a; Petryayeva et al., 2013), silica (Vanblaaderen
and Vrij, 1992; Giri et al., 2005, 2007; Burns et al., 2006), gold
(Boisselier and Astruc, 2009; Arvizo et al., 2010), magnetic mate-
rials (Arruebo et al., 2007; Banerjee et al., 2010; Haun et al.,
2010), and carbon-based materials (Prato et al., 2008; Jain, 2012).
Semiconductor nanoparticles, or quantum dots, have a narrow
and tunable emission spectrum, a broad excitation spectrum, and
do not photobleach. These characteristics are attractive for opti-
cal imaging, however, many quantum dots are synthesized from
heavy metal elements and hence toxicity is a concern. Silicon
dioxide (silica), the most widely used oxide, is a versatile mate-
rial that is relatively inert. Silica can be used to encapsulate other
materials or cargoes and the surface can be conjugated using
silane chemistry. Silica can be synthesized with nanometer scale
pores (mesoporous silica) that can be used to hold other cargoes.
Of the metallic materials, gold is widely used for biological appli-
cations as it is easy to synthesize, can be functionalized using thiol
chemistry, and is relatively inert. Many of the noble metals absorb
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electromagnetic radiation in the visible range of the spectrum
(plasmon absorbance), and have been explored for hyperther-
mia therapy. Gold nanoparticles conjugated with PEG and tumor
necrosis factor alpha (TNFα are being developed for targeted
cancer therapy (Libutti et al., 2010).
Ferromagnetic materials, such as iron oxide (magnetite,
Fe3O4), iron, cobalt, and nickel offer an additional degree of
freedom in the synthesis of nanoparticles for nanomedicine
(Arruebo et al., 2007). Very small ferromagnetic nanoparti-
cles (typically < 10 nm) have no intrinsic magnetization in the
absence of a magnetic field, and hence do not aggregate in col-
loidal suspension. These superparamagnetic nanoparticles can be
manipulated in an external field providing a simple method for
spatial manipulation and washing. Magnetic nanoparticles, such
as superparamagnetic iron oxide (SPIO) nanoparticles have been
used for magnetic resonance imaging (MRI) and hyperthermia
therapy (Yu et al., 2013).
Carbon-based nanoparticles have exploited the small size
and unique properties of buckyballs, carbon nanotubes, and
grapheme (Yu et al., 2013). Combinations of organic and inor-
ganic materials, taking advantage of specific materials and struc-
tures have also been widely explored in multifunctional nanopar-
ticle platforms.
Hybrid nanoparticles with organic and inorganic compo-
nents or associated combinations of inorganic nanostructures
provide further opportunities for introducing multiple func-
tionalities. These systems can exploit the biocompatibility of
organic nanoparticles, while still retaining the stability and func-
tion of inorganic nanoparticles. Inorganic nanoparticle conju-
gates allow for multimodal imaging and theranostic applications.
Examples include constructs such as liposomes filled with mag-
netic nanoparticles (Sailor and Park, 2012), coordination polymer
nanoparticles (Novio et al., 2013), and metal-organic frameworks
(Horcajada et al., 2012).
TARGETING MOIETIES (ANTIBODIES, APTAMERS, SMALL MOLECULES,
ETC.)
Active targeting of a nanoparticle is a way to minimize uptake in
normal tissue and increase accumulation in a tumor. Strategies
for active targeting of tumors usually involve targeting surface
membrane proteins that are upregulated in cancer cells (Huynh
et al., 2010; Hanahan and Weinberg, 2011). While this strategy is
widely used, tumor cell populations are extremely heterogeneous
and expression levels can vary significantly. Targeting molecules
are typically antibodies (Dill et al., 1994; Arruebo et al., 2009;
Chames et al., 2009), antibody fragments (Holliger and Hudson,
2005), aptamers (Keefe et al., 2010; Hu and Zhang, 2013), or small
molecules (Figure 1).
Accumulation of a delivery system at a tumor site by the EPR
effect is dependent in part on the concentration in the circulation.
Processes such as clearance by the MPS or uptake in normal tis-
sue decrease the concentration in circulation and hence decrease
the accumulation in the tumor. Active targeting can provide an
additional sink for a nanoparticle platform since expression of
target molecules is usually differential in that the target is highly
expressed in tumor cells but expressed at low levels in other
cell types in the vascular system. Since the surface area of the
FIGURE 1 | Examples of targeting molecules. (A) Antibodies are typically
around 150 kDa or about 15 × 5nmwith two antigen binding sites. (B)
xPSM-A10 is a 18.5 kDa aptamer with a binding affinity of about 10−8 M−1 for
the extracellular portion of the prostate-specific membrane antigen (PSMA)
(Lupold et al., 2002). (C) The glutamate lysine urea small molecule targets
PSMA (473Da) (Banerjee et al., 2008). (D) The RGD peptide sequence
(604Da) binds to cell surface integrins, upregulated in many tumor types.
vasculature is much larger than the tumor, active binding in nor-
mal tissue can be significant, even for targets that are expressed
at relatively low levels (Jain, 2005). Furthermore, targeting moi-
eties may themselves be targets for receptors on phagocytic cells,
as described above.
Antibodies
Monoclonal IgG antibodies (mAbs) are widely used for protein
recognition and targeting since they have two epitope binding
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sites, high selectivity, and high binding affinity (Chames et al.,
2009). Antibodies are the largest of the targeting ligands, approx-
imately 150 kDa or about 15 nm long and about 5 nm in diame-
ter. The binding (dissociation) constants for antibody—antigen
interactions vary over a wide range from 10−6 to 10−9 M, but
can be as high as 10−12 M for high affinity antibodies (Dill
et al., 1994). For targeting applications, the Fc region of the anti-
body can be a disadvantage if it is accessible to Fc receptors on
macrophages, which can lead to increased accumulation in the
liver and spleen (Allen, 2002).
Antibody fragments
Antigen binding sites represent only a small part of the overall
size of antibodies. F(ab′)2 fragments retain both antigen bind-
ing sites of the antibody coupled by disulfide linkages. Cleavage
of the disulfide bond under reducing conditions yields two Fab′
fragments with sulfhydryl groups that can be used for coupling to
the targeting platform. Single chain variable fragments maintain
only the variable regions (variable light chain and variable heavy
chain) of one arm of an antibody.
Aptamers
Aptamers are folded single strand oligonucleotides, 25–100
nucleotides in length (8–25 kDa) that bind to molecular targets
(Tuerk and Gold, 1990; Keefe et al., 2010). High throughput
screening methods can be used for rapid selection of aptamers for
specific targets (Bunka and Stockley, 2006). Macugen, approved
for use in the treatment of macular degeneration in 2004, is
currently the only FDA approved aptamer (Adamis et al., 2006).
Small molecules
Small molecules for targeting include peptides, growth factors,
carbohydrates, ureas, and receptor ligands (Weissleder et al.,
2005). Specific examples include folic acid, transferrin, and the
RGD peptide sequence. Folic acid (441 Da) is recognized by the
folic acid receptor and is expressed in normal epithelial cells
but is overexpressed in many cancer types, especially ovarian,
brain, and lung cancers (Kamen and Smith, 2004; Hilgenbrink
and Low, 2005; Parker et al., 2005; Chames et al., 2009; Muller
and Schibli, 2013; Naumann et al., 2013). Folic acid is essen-
tial for amino acid synthesis and hence for cell survival and
proliferation, and has a high affinity (Kd < 10−9 M) (Hartmann
et al., 2007). Transferrin is a chelating protein that regulates
the supply of iron into cells via receptor-mediated endocyto-
sis (Kresse et al., 1998). The transferrin receptor is expressed
at low levels in most normal tissues but is overexpressed in
many tumor types (Daniels et al., 2012). The RGD (Arg-Gly-
Asp) peptide is a target for integrins (e.g., αvβ3) on the cell
surface (Ruoslahti, 1996; Hynes, 2002). RGD is a component of
the extracellular matrix protein fibronectin and promotes cell
adhesion and regulates cell migration, growth, and proliferation
(Ruoslahti, 1996; Hynes, 2002). A cyclic peptide containing the
RGD sequence is widely used for targeting to integrins (Haubner
et al., 1996). The upregulation of integrins is promoted by angio-
genic factors in several cancer types (Dechantsreiter et al., 1999;
Hosotani et al., 2002; Furger et al., 2003; Sheldrake and Patterson,
2009).
TUMOR ACCUMULATION AND TARGETING EFFICIENCY
In preclinical studies the efficacy of a drug is often determined
from the time dependence of tumor size or from the fraction
of animals that survive after a candidate therapy. These param-
eters are particularly useful in assessing the potential therapeutic
benefit of a new delivery system but integrate many factors. An
additional parameter that is important in assessing the potential
efficacy of delivery systems is the tumor accumulation or tar-
geting efficiency—the fraction of an intravenously administered
dose that accumulates in a tumor (%ID). Despite the impor-
tance of this parameter, very few measurements are reported in
the literature.
We have reviewed 40 pre-clinical studies of delivery systems
employing passive targeting (Supplementary Table S1), and 34
pre-clinical studies employing active targeting (Supplementary
Table S2). Only studies reporting quantitative results of tumor
accumulation were selected. Analysis of these pre-clinical studies
highlights the need for guidelines to improve the overall impact of
research in this field. Despite the importance of pharmacokinet-
ics and tumor accumulation in assessing the efficiency of delivery
systems, very few preclinical studies report quantitative results
that can be used to develop design rules for nanomedicines.
PASSIVE TARGETING
Delivery systems used in pre-clinical studies exploiting passive
targeting include liposomes (Harrington et al., 2000; Wang et al.,
2006; Soundararajan et al., 2009; Zheng et al., 2009; Huang et al.,
2011; Chen et al., 2012a; Coimbra et al., 2012; Hsu et al., 2012;
Mahakian et al., 2014) (Kheirolomoom et al., 2010), micelles
(Yokoyama et al., 1999; Le Garrec et al., 2002; Kawano et al.,
2006; Reddy et al., 2006; Rijcken et al., 2007; Kim et al., 2008;
Hoang et al., 2009; Shiraishi et al., 2009; Blanco et al., 2010;
Sumitani et al., 2011; Wang and Gartel, 2011; Zhao et al., 2012;
Miller et al., 2013; Zhu et al., 2013), gold nanoparticles (Hainfeld
et al., 2006; Von Maltzahn et al., 2009; Puvanakrishnan et al.,
2012), iron oxide nanoparticles (Ujiie et al., 2011), silica nanopar-
ticles (Chen et al., 2012b; Di Pasqua et al., 2012), carbon-based
nanostructures (Liu et al., 2011; Robinson et al., 2012; Rong
et al., 2014), quantum dots (Sun et al., 2014), and hybrid nano-
materials (Balogh et al., 2007; Tinkov et al., 2010; Yang et al.,
2012) (Paraskar et al., 2012) (Ohno et al., 2013) (Supplementary
Table S1).
Of the 40 pre-clinical studies, only a few (4/40) reported tumor
accumulation as %ID, while the remainder reported normalized
accumulation as %ID/g or %ID/cc. The tumor accumulation
varies over a wide range from 0.1 to 35%ID/g at 24 h post-
injection. Passive delivery systems are generally pegylated and
have sizes in the range from 2 to 200 nm. However, there are
no clear trends in terms of identifying physico-chemical parame-
ters that influence the pharmacokinetics or tumor accumulation.
Although pegylation is generally assumed to increase circulation
time and hence increase tumor accumulation, there is no con-
sistent difference in tumor accumulation between pegylated and
non-pegylated delivery systems.
Similarly, there is no obvious dependence on the size or
shape of the delivery system. For example, the tumor accumu-
lation of pegylated liposomes around 100 nm in diameter in three
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studies varied from 0.4 to 11%ID/g (Soundararajan et al., 2009;
Kheirolomoom et al., 2010; Hsu et al., 2012). The large varia-
tion is likely due to the differences in xenograft cell line, tumor
size, and dose. Similarly, tumor accumulation in two pre-clinical
studies of 30 nm diameter micelles with different polymer for-
mulations were 1.5%ID/g (Yokoyama et al., 1999) and 9.5%ID/g
(Blanco et al., 2010). These two studies used different mod-
els (orthotopic vs. xenograft), tumor cell line (A549 vs. C26),
tumor size (200 vs. 100mm3), and injected dose (30–50mg/kg
vs. 10mg/kg). These differences in experimental design limit the
ability to compare the two different micelle formulations. These
examples highlight the difficulty in comparing pre-clinical trials
due to the variability in experimental design.
ACTIVE TARGETING
Targeted delivery systems used in quantitative pre-clinical stud-
ies include silica (Benezra et al., 2011; Tang et al., 2012; Chen
et al., 2013), gold (Melancon et al., 2008; Lu et al., 2009, 2010;
Chanda et al., 2010; Choi et al., 2010; Morales-Avila et al., 2011;
Chattopadhyay et al., 2012), liposomes (Iyer et al., 2011; Helbok
et al., 2012; Petersen et al., 2012), micelles (Hu et al., 2008; Penate
Medina et al., 2011; Zhang et al., 2011b; Fonge et al., 2012; Helbok
et al., 2012) (Rossin et al., 2005; Khemtong et al., 2009; Zhan et al.,
2010; Poon et al., 2011; Zhang et al., 2011a; Xiao et al., 2012), iron
oxide (Natarajan et al., 2008; Kumar et al., 2010; Yang et al., 2011),
graphene (Hong et al., 2012; Cornelissen et al., 2013; Shi et al.,
2013), gadolinium (Oyewumi et al., 2004), polymer nanocarriers
(Kunjachan et al., 2014), nanoemulsions (Ohguchi et al., 2008),
quantum dots (Gao et al., 2010), and hybrid (Cheng et al., 2014)
(Supplementary Table S2). Similar to passive targeting, few stud-
ies (3/34) report %ID rather than %ID/g. The most common
targeting ligands are antibody based (9/34 studies), the RGD pep-
tide sequence (10/34), and folate (5/34). Targeting efficiencies
obtained using RGD peptides, folate, antibodies, and antibody
fragments are typically between 1 and 15%ID/g (Supplementary
Table S2).
Assessing the efficiency of a targeting ligand in increasing
tumor accumulation is complicated by the different control
experiments used in these studies. The contribution of pas-
sive targeting was assessed by measuring tumor accumulation
of the delivery system without attachment of the targeting lig-
and (20/34), with attachment of a non-specific ligand (2/34),
pre-injection with a blocking molecule or treatment (10/34), or
with a xenograft formed from a cell line that did not express
the target molecule (2/34). Several studies (4/34) did not report
a control experiment. Each control experiment has advantages
and disadvantages. For example, removing a targeting ligand
from a delivery system may alter the physico-chemical proper-
ties and hence change the pharmacokinetics. As described in
more detail below, xenografts formed from different cell lines
may have significantly different vascularization and hence the
rate of extravasation to the tumor site by the EPR effect may
be significantly different. Pre-injection with a blocking molecule
may not completely prevent binding to the target molecule or
may reduce binding in normal tissue. To account for these
potential complications, a few studies (3/34) used multiple
controls.
Of the 30 pre-clinical studies that reported control exper-
iments, 33% (10/30) showed less than a two-fold increase in
targeting compared to the control, and 50% (15/30) showed an
increase in tumor accumulation of more than 2%ID/g with the
targeting ligand. For example, a tumor accumulation of 9%ID
was reported for SPIONS with anti-ChL6 2 days post-injection
compared to 1% without the targeting antibody (Natarajan et al.,
2008). A tumor accumulation of 7 ± 1%ID was reported for
gadolinium nanoparticles with a folate targeting ligand, and 9 ±
4%ID in the control with no targeting ligand (Oyewumi et al.,
2004). While active targeting of a delivery system to a tumor site
has the potential to reduce unwanted side effects, these studies
highlight the difficulties in assessing targeting efficiency due to the
large differences in experimental design and the range of controls
used to assess the contribution of passive targeting.
TUMOR ACCUMULATION
In general, the uptake of a delivery system in a tumor tends
to increase post-injection but then decreases at longer times
(Supplementary Table S1 and S2). For example, tumor accumu-
lation of radiolabeled liposomes increased to 11.3%ID/g over the
first 24 h, then decreased to 6.1%ID/g after 72 h (Hsu et al., 2012).
Tumor accumulation of self-activating quantum dots increased
to 13%ID/g over the first 24 h, but decreased to 11%ID/g after
42 h (Sun et al., 2014). Similarly, tumor accumulation of pegy-
lated micelles with a gelatinase binding peptide was reported to
increase to almost 18% ID/g over the first 6 h, but decreased to 2%
ID/g after 24 h (Penate Medina et al., 2011). Tumor accumulation
of gold nanoparticles with the RGD peptide increased to 3.65%
ID/g over the first hour followed by a decrease by almost half to
1.94% ID/g 24 h post-injection (Morales-Avila et al., 2011). The
details of the time dependence of tumor accumulation are impor-
tant in understanding the pharmacokinetics, the EPR effect, and
the limitations to accumulating a drug at the tumor site. In many
studies, an insufficient number of time points precludes detailed
analysis of pharmacokinetics and tumor accumulation.
The cell line used in forming a xenograft can have significant
influence on tumor accumulation and efficacy. In the 74 quanti-
tative pre-clinical trials reviewed here, 35 different cell types were
used to form xenografts. The most common cell lines were the
4T1 murine breast cancer cell line (10/71) and the C26 colon
carcinoma cell line (10/71), both of which form highly vascu-
larized tumors. Tumor accumulation of micelles with the RGD
peptide was 6%ID/g in a mouse model with a C26 xenograft
and 3%ID/g with a less leaky BxPC3 xenograft (Kunjachan et al.,
2014), highlighting the need for standardization of cell lines.
Tumor size can have a significant influence on tumor accu-
mulation. For example, a study using radiolabeled liposomes
compared targeting efficiency among tumors of different sizes
using the KB cell line (Harrington et al., 2000). The tumor
accumulation for small tumors (≤0.1 g) was around 15%ID/g,
whereas for larger tumors (≥1 g) was only 3%ID/g.
GUIDELINES FOR PRE-CLINICAL STUDIES OF DELIVERY
SYSTEMS
While the physico-chemical properties of delivery systems are
expected to exert a significant influence on pharmacokinetics,
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tumor accumulation, and biodistribution, there are numerous
problems in comparing pre-clinical studies. In particular, differ-
ences in cell line and tumor size, dose, lack of good pharma-
cokinetics data, and differences in reporting make meta-analysis
extremely difficult and are a limitation to progress in the
field (Table 4). Similarly, physico-chemical properties of the
delivery system such as size, surface properties (i.e., pegyla-
tion), zeta potential, targeting ligand density, and stability in
blood or serum at physiological temperature are not uniformly
reported.
For example, results are usually reported as percent of initial
administered dose per gram of tumor (%ID/g), which is only
useful if the tumor mass is also reported. For example, a tumor
accumulation of 10%ID/g is 10% of the initial dose for a 1 g
Table 4 | Summary of limitations to pre-clinical studies of
nanomedicines that hinder broad assessment of design rules.
Problem Solution
Total tumor accumulation (%ID) is
not always reported
Report tumor accumulation as %ID
(and %ID/g)
Inconsistent reporting of tumor
size/weight
Report tumor size/weight
Inconsistent reporting of dose Report dose as total number of
nanoparticles injected
Along with other parameters such
as drug loading, drug concentration
(and/or drug amount), and activity
of dose (gamma counter)
Inconsistent reporting of
physico-chemical properties
Report standard physico-chemical
properties (e.g., size, zeta potential,
surface coating, stability under
physiological conditions)
Tumor accumulation reported at
different time points
Report tumor accumulation at
standard time points (e.g., 1 and
24 h post-injection). Detailed
pharmacokinetics (concentration in
blood and tumor) at multiple time
points is preferred
Variation in tumor characteristics
(type, size, vascularization, etc.)
Standardize tumor type and size
(e.g., C26 or 4T1; 1 cm diameter)
More difficult for active targeting
depending on target molecule
Variation in controls used in active
targeting
Report control studies for delivery
system with no targeting ligand and
any differences in physico-chemical
properties. Report other control
studies as necessary
Variation in animal models (mouse,
rat, etc.) and differences in drug
concentration compared to humans
Use mouse xenograft model for
initial pre-clinical studies
Different detection methods used
to assess tumor accumulation
Perform validation using other
method(s)
tumor but 1% of the initial dose for a 0.1 g tumor. These dif-
ferences are significant in terms of the efficiency of delivery and
minimizing unwanted side effects in normal tissue. In some cases
tumor characteristics such as tumor diameter or approximate
tumor volume are reported, however, these parameters can only
be used to estimate the absolute percentage of the initial dose.
Mouse models are widely used for research studies of disease
progression and the development of new therapies (Frese and
Tuveson, 2007). Rat and rabbit models are also commonly used
for pre-clinical studies. Standard tumor models include subcu-
taneous xenografts of human cell lines or explants, orthotopic
xenografts, and genetically engineered mouse models (Frese and
Tuveson, 2007; Chen et al., 2012a).While these models are invalu-
able for pre-clinical studies, differences in physiology can lead to
differences in circulation and tumor accumulation compared to
humans (Steichen et al., 2012).
Xenografts represent a relatively straightforward model to
study the pharmacokinetics, tumor accumulation, and biodistri-
bution of a nanomedicine, however, tumor characteristics vary
considerably with cell line and size (Harrington et al., 2000; Jain
and Stylianopoulos, 2010). The density and vascularization of
tumors of similar size can also vary significantly. Highly inva-
sive cell lines often form more highly vascularized tumors, for
example xenografts of colon cancer cell lines have vasculature that
is much more leaky than pancreatic cancer cell lines. Therefore,
tumor uptake by the EPR effect is expected to be strongly depen-
dent on the cell line used. Establishing a standard cell line
and tumor size for xenografts would greatly enhance compar-
ison of pre-clinical trials of delivery systems (Table 4). While
this is feasible for passive delivery systems, active targeting often
requires the use of specific cell lines that overexpress a particular
biomarker.
Tumor accumulation is usually measured using a gamma
counter, positron emission tomography (PET), or inductively
coupled plasmamass spectroscopy (ICP-MS). The methods using
a gamma counter or PET require that a suitable radiolabel
is conjugated to the drug delivery platform. With a gamma
counter, the radioactivity of the resected tumor is measured and
compared to the radioactivity of the dose. To determine the
tumor accumulation from PET scans, reconstructed 3D regions
of interest are drawn around the tumor. The activity per unit
mass can then be determined after correcting for decay and
tissue density. An alternative to using a radiolabel to measure
the tumor accumulation is to use ICP-MS to determine the
amount of one or more elemental components in the deliv-
ery system and to compare to the initial dose. However, this
method requires a component of the delivery system to be dis-
tinguishable from biological matter. In most pre-clinical studies
only one of the methods is used to determine pharmacokinet-
ics and tumor accumulation and hence there is no independent
verification.
Tumor accumulation is expected to be dependent on the dose
and time post-injection, and hence time-course studies at dif-
ferent doses are important for full characterization. In many
cases, tumor accumulation is determined only at one or two time
points therefore limiting analysis of the pharmacokinetics which
is crucial for developing design rules.
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SUMMARY
Nanoparticle-based delivery systems provide new opportunities
to overcome the limitations associated with traditional drug ther-
apy and to achieve both therapeutic and diagnostic functions in
the same platform. The efficiency of drug or gene delivery to a
tumor site is dependent on the physico-chemical properties of the
delivery platform and a range of physiologically imposed design
constraints including clearance by the mononuclear phagocyte
system and extravasation from circulation at the tumor site by
the enhanced permeability and retention effect.
The lack of uniformity in pre-clinical trials of nanoparticle-
based delivery systems has prevented systematic comparison of
these studies and has been an impediment to developing design
rules for new systems or specific applications. Of the large num-
ber of pre-clinical trials, surprisingly few report quantitative data
on parameters that would be useful in developing design rules
for nanomedicines. The poor experimental design and variability
of experimental conditions also contribute to slow development
of the field and the lack of clinical impact. We highlight some
of the problems with pre-clinical trials nanoparticle-based deliv-
ery systems and suggest some solutions to increase the impact of
individual studies.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: http://www.frontiersin.org/journal/10.3389/fchem.
2014.00069/abstract
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